Alexander Osowa, MD
Family Medicine · Jackson, MSNPI 1316910755
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,255 of the $3,126 with a category attached, or 72.1%. 23 manufacturers reported payments, led by Eli Lilly at 28.3% of the total. Reporting peaked in 2024 at $1,129 and has fallen 91.3% since, to $98 in 2025.
Across 108 payments — averaging $28.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$884
- GSK$456
- Novo Nordisk$406
- Lilly USA, LLC$212
- AstraZeneca$179
- Boehringer Ingelheim$158
- plus $831 from 17 others
Across 315 payments — averaging $7009.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1M
- GSK$340K
- AbbVie$255K
- Astrazeneca UK Limited$150K
- Eisai Inc.$113K
- Sanofi US Services Inc.$111K
- plus $236K from 7 others
What the payments were for
- Travel & lodging$85727%
- Food & beverage$2,25572%
- Entertainment$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 8 | $884 |
| GSK | 9 | $456 |
| Novo Nordisk | 26 | $406 |
| Lilly USA, LLC | 12 | $212 |
| AstraZeneca | 5 | $179 |
| Boehringer Ingelheim | 4 | $158 |
| Pfizer | 7 | $129 |
| Bayer | 6 | $121 |
| Novartis | 6 | $85 |
| Supernus Pharmaceuticals, Inc. | 3 | $66 |
| AbbVie(2 entities) | 3 | $66 |
| Edwards Lifesciences | 2 | $57 |
| Exact Sciences | 3 | $54 |
| Abbott | 2 | $42 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| Merck | 2 | $35 |
| Dexcom, Inc. | 2 | $32 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Amgen | 1 | $18 |
| Linus Health, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Optos, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,126 in reported general payments places this provider in the 75th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TradjentaLinagliptin | 43 | $55,810 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 12 | $51,046 |
| OzempicSemaglutide | 23 | $40,630 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $30,456 |
| TrulicityDulaglutide | 17 | $23,083 |
| JardianceEmpagliflozin | 17 | $22,376 |
| FarxigaDapagliflozin Propanediol | 13 | $19,364 |
| EliquisApixaban | 19 | $18,952 |
| EntrestoSacubitril/Valsartan | 14 | $17,205 |
| MounjaroTirzepatide | 11 | $11,473 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $9,946 |
| XareltoRivaroxaban | 11 | $8,933 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 16 | $4,896 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 16 | $3,527 |
| Gabapentin | 55 | $1,111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTradjenta, Jardiance | $158 | $78,18660 claims |
| Novo NordiskOzempic | $406 | $40,63023 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $456 | $38,87955 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $212 | $34,55628 claims |
| AstraZenecaFarxiga | $179 | $19,36413 claims |
| PfizerEliquis | $129 | $18,95219 claims |
| NovartisEntresto | $85 | $17,20514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Jackson
- Dava ClevelandJackson$100K
- Andrea PhillipsJackson$96K
- Massie HeadleyJackson$10K
- Russell CarlisleWesson$1.6M
- Keith StokesLexington$654K
- Walter CarnahanSouthaven$146K
- Karen WhitneyWhitfield$117K
- Kristi TrimmRidgeland$34K
- Tana CooperBiloxi$25K
- Delora DenneyPicayune$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.